Molecular links between endometriosis and cancer

Gynecological Endocrinology

Volumn 28, Issue 8, 2012, Pages 577-581

  Pollacco, Joel ^a   Sacco, Keith ^a   Portelli, Mark ^a   Schembri Wismayer, Pierre ^a   Calleja Agius, Jean ^a,b  

^a UNIVERSITY OF MALTA   (Malta)

^b MATER DEI HOSPITAL   (Malta)

Author keywords

Apoptosis; cancer; cytokines; endometriosis

Indexed keywords

ESTROGEN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; DISEASE ASSOCIATION; DNA REPLICATION; ENDOMETRIOSIS; ENDOMETRIOSIS INDUCED CARCINOMA; GENE MUTATION; GENETIC ASSOCIATION; GYNECOLOGIC CANCER; HETEROZYGOSITY LOSS; HUMAN; MACROPHAGE; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; STEM CELL; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; APOPTOSIS; CARCINOMA, ENDOMETRIOID; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; MACROPHAGES; MUTATION; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS;

EID: 84863870101     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.650761     Document Type: Article

References (59)

1. Germeyer A, Giudice LC. How does endometriosis cause infertility? In: Tulandi T, Redwine D, editors. Endometriosis Advances and Controversies. New York: Marcel Dekker Inc; 2004. pp 151.
2. Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril 2010;94:1212-1217.
3. Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, et al. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 2002;21:3517-3524.
4. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002;94:2935-2940.
5. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83:196-203.
6. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-1256.
7. Varma R, Rollason T, Gupta JK, Maher ER. Endometriosis and the neoplastic process. Reproduction 2004;127:293-304.
8. Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson IP, Kennedy SH. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006;119:556-562.
9. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 2002;123:217-226.
10. Melin A, Sparén P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006;21:1237-1242.
11. Aris A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res 2010; 3:2.
12. Kusaka M, Mikuni M, Nishiya M. A case of high-grade endometrial stromal sarcoma arising from endometriosis in the cul-de-sac. Int J Gynecol Cancer 2006;16:895-899.
13. Leng J, Lang J, Guo L, Li H, Liu Z. Carcinosarcoma arising from atypical endometriosis in a cesarean section scar. Int J Gynecol Cancer 2006;16:432-435.
14. Garavan F, Grainger R, Jeffers M. Endometrioid carcinoma of the urinary bladder complicating vesical Mullerianosis: a case report and review of the literature. Virchows Arch 2004;444:587-589.
15. Jimenez RE, Tiguert R, Hurley P, An T, Grignon DJ, Lawrence D, Triest J. Unilateral hydronephrosis resulting from intraluminal obstruction of the ureter by adenosquamous endometrioid carcinoma arising from disseminated endometriosis. Urology 2000;56:331.
16. Salerno MG, Masciullo V, Naldini A, Zannoni GF, Vellone V, Scambia G. Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosis. Gynecol Oncol 2005;99:749-752.
17. Park HM, Lee SS, Eom DW, Kang GH, Yi SW, Sohn WS. Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix: a case report. J Korean Med Sci 2009;24:767-771.
18. Han AC, Hovenden S, Rosenblum NG, Salazar H. Adenocarcinoma arising in extragonadal endometriosis: an immunohistochemical study. Cancer 1998;83:1163-1169.
19. Paglieri LJ, Pinkoski MJ, Green DR., Apoptosis signalling: A means to an end: Chapter 331. In: Bradshaw RA, Dennis EA, editors-in-chief. Handbook of Cell Signalling, Vol. 3. United States of America: Elsevier Science; 2003. pp 431-439.
20. Underwood JCE, Cross SS. General and systematic pathology 5th ed. China: Elsevier Limited; 2009. pp 248.
21. Horiuchi A, Osada R, Nakayama K, Toki T, Nikaido T, Fujii S. Ovarian yolk sac tumor with endometrioid carcinoma arising from endometriosis in a postmenopausal woman, with special reference to expression of alpha-fetoprotein, sex steroid receptors, and p53. Gynecol Oncol 1998;70:295-299.
22. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000;156:409-417.
23. Akahane T, Sekizawa A, Purwosunu Y, Nagatsuka M, Okai T. The role of p53 mutation in the carcinomas arising from endometriosis. Int J Gynecol Pathol 2007;26:345-351.
24. Prefumo F, Venturini PL, Fulcheri E. Analysis of p53 and c-erbB-2 expression in ovarian endometrioid carcinomas arising in endometriosis. Int J Gynecol Pathol 2003;22:83-88.
25. Balkwill, F., Charles, K. A. and Mantovani, A. 2007. The Links between Inflammation and Cancer. The Cancer Handbook.
26. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-1467.
27. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003;171:6448-6456.
28. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266.
29. Fenton HJH. Oxidation of tartaric acid in presence of iron. J Chem Soc 1894;65:899-810.
30. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, Fujii S. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40.
31. Stricker TP, Kumar V. Neoplasia: Chapter 7. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease. 8th ed. China: Elsevier Saunders; 2010. pp 310.
32. Edenburg HJ. DNA replication, recombination and repair. Chapter 4. In: Devlin TM, editor. Textbook of Biochemistry With Clinical Correlations. United States of America: Wiley Liss; 2006. pp 152-153, 159, 159-160 and 164-165.
33. Benz CC, Yau C. Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev Cancer 2008;8:875-879.
34. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;7:59.
35. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904.
36. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005;175:1197-1205.
37. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:302-306.
38. Del Carmen MG, Smith Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer 2003;98:1658-1663.
39. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
40. Yokoyama Y, Takahashi Y, Morishita S, Hashimoto M, Niwa K, Tamaya T. Telomerase activity in the human endometrium throughout the menstrual cycle. Mol Hum Reprod 1998;4:173-177.
41. Kim CM, Oh YJ, Cho SH, Chung DJ, Hwang JY, Park KH, Cho DJ, et al. Increased telomerase activity and human telomerase reverse transcriptase mRNA expression in the endometrium of patients with endometriosis. Hum Reprod 2007;22:843-849.
42. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60:7052-7056.
43. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998;58:1707-1712.
44. Hsieh YY, Lin CS. P53 codon 11, 72, and 248 gene polymorphisms in endometriosis. Int J Biol Sci 2006;2:188-193.
45. Jiang X, Hitchcock A, Bryan EJ, Watson RH, Englefield P, Thomas EJ, Campbell IG. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996;56:3534-3539.
46. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-1543.
47. Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, Zannoni G, et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 2002;102:398-406.
48. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB, Herman JG. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999;155:1767-1772.
49. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998;17:2413-2417.
50. Agoulnik IU, Tong XW, Fischer DC, Körner K, Atkinson NE, Edwards DP, Headon DR, et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004;89:6340-6347.
51. Jang SJ, Mao L. Methylation patterns in human androgen receptor gene and clonality analysis. Cancer Res 2000;60:864-866.
52. Mayr D, Amann G, Siefert C, Diebold J, Anderegg B. Does endometriosis really have premalignant potential? A clonal analysis of laser-microdissected tissue. FASEB J 2003;17:693-695. DOI: 10.1096/fj.02-0562fje.
53. Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006;12:49-56.
54. Dmowski WP, Gebel HM, Braun DP. The role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand Suppl 1994;159:7-14.
55. Sacco K, Portelli M, Pollacco J, Schembri-Wismayer P, Calleja-Agius J. The role of prostaglandin E(2) in endometriosis. Gynecol Endocrinol 2011. [Epub Ahead of Print].
56. Lin YJ, Lai MD, Lei HY, Wing LY. Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 2006;147:1278-1286.
57. Koninckx RF. Epidemiology of endometriosis. In: Tulandi T, Redwine D, editors. Endometriosis Advances and Controversies. New York: Marcel Dekker Inc; 2004. pp 16.
58. Ricciardelli C, Oehler MK. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009;62:270-275.
59. Cancer Research UK [Internet]. Ovarian Cancer UK Incidence Statistics, Cancer Research UK. Cited Jul 8, 2011. Available from: http://info. cancerresearchuk.org/cancerstats/types/ovary/incidence/